TissueTech has raised approximately $55.3 million in a new round of equity financing, according to a recently posed SEC filing.
The Doral, Fla.-based company makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business).
Money in the round came from three unnamed investors, with the first sale dated as having occurred on April 9, according to the filing.
The company is looking to raise an additional $27 million, which would bring the total raised up to approximately $82.3 million, according to the SEC filing.
TissueTech said that it plans to use a $10 million of the proceeds to repurchase from common stockholders on a pro rata basis, according to the SEC filing.
The company has not yet announced any other plans for the funds.